Morphomolecular pathology: setting the framework for a new generation of pathologists by Jones, J. Louise et al.
Morphomolecular pathology: setting the
framework for a new generation of
pathologists
J Louise Jones*,1, Karin A Oien2, Jessica L Lee3 and Manuel Salto-Tellez*,4
1Centre for Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London EC1M
6BQ, UK; 2Institute of Cancer Sciences—Pathology, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow G61 1QH, UK; 3National Cancer Research Institute, London EC1V 4AD, UK and 4Northern Ireland
Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast BT7 1NN,
Northern Ireland
Molecular diagnostics and precision medicine are now a reality.
With the roll-out of the 100 000 Genomes Project, one of the most
ambitious initiatives of its kind worldwide (Siva, 2015), pathways
are being established for the adoption of genomic medicine across
the National Health Service of the UK, the largest existing
operation providing universal healthcare for its citizens. This
requires a transformation in the way in which the NHS handles
patient samples and integrates complimentary analyses on tissues
to direct patient management. New approaches in molecular
pathology are essential to address the challenges of this new era of
genomic medicine. Indeed, how pathologists are able to transit
from an approach to tissue diagnostics driven by morphology
alone towards a true morphomolecular ethos (Salto-Tellez, 2007) is
arguably the most important test for tissue and cellular pathologists
(histopathologists or surgical pathologists and cytopathologists) in
the last 60 years.
This is far from the first transformation that pathology has faced
since its inception. Historically (Tweel and Taylor, 2010),
pathology has evolved from a discipline based on the under-
standing of gross and microscopic physiopathology to an
established medical diagnostic specialty. However, over the last 6
decades since the discovery of the DNA helix, the challenge to use
our increased understanding of the molecular basis of disease to
broaden our diagnostic armamentarium has not been embraced as
promptly as it could have been (Chan and Salto-Tellez, 2012). This
is in contrast with other disciplines within laboratory medicine: for
example, molecular haematology is embedded within clinical
haematology services, modern virology is almost exclusively
molecular, and contemporary genetics has almost fully completed
the transition to molecular testing. This is surprising when one
takes into account the many tests already underway in tissues and
cells. For example, lymphomas (Siok-Bian et al, 2008), sarcomas
(Siok-Bian et al, 2008), and tumours from the central nervous
system (Rushing and Wesseling, 2015) need systematic molecular
testing according to the international guidelines; moreover,
molecular testing of colorectal, lung, breast, and some skin cancers
are the epitome of what we now call precision or stratified
medicine, or therapeutic pathology (Salto-Tellez, 2013). Most of
these tests are equally applicable to histology or cytology samples
(Salto-Tellez, 2015). In addition, many of the emerging challenges
in modern medicine need to be addressed by the interrogation of
tissues and cells using a combination of morphological and
molecular techniques such as next-generation sequencing in
routine diagnostics (Salto-Tellez and Castro, 2014), or the delivery
of cancer immunotherapy supported by robust immune biomar-
kers (Balar and Weber, 2017). In this evolution, pathologists need
to accept that techniques that are part of our traditional
armamentarium develop a new meaning, and new rules. This has
already been exemplified by so-called therapeutic immunohisto-
chemistry (Mccourt et al, 2012) such as ER, PR, c-erbB2/Her2,
ALK, and PD-L1, all of which require more stringent handling of
tissues and quantitative interpretation.
Beyond the diagnostic setting, there has been renewed interest
in tissue pathology in relation to what it can offer in large research
environments. There is a clear realisation that effective and robust
translational medicine requires large, high-quality, well-annotated
tissue samples and expert pathology input. Reports indicate that
pathology review as part of clinical trials can lead to a change in
diagnosis sufficient to change management in up to 10% of cases
(Nguyen et al, 2004), underscoring the importance of accurate
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histological assessment. However, beyond this traditional pathol-
ogy role, professional biobanking (Lewis et al, 2016), digital
pathology (Hamilton et al, 2014), pathology bioinformatics and
information management (Mcart et al, 2015), and molecular
pathological epidemiology (Hamada et al, 2016) are further areas
where pathology input can have an impact on translational studies.
In spite of this recognition, one of the most puzzling paradoxes
in pathology is how little training programmes have evolved in
parallel with these needs, and failed to embrace this new paradigm
of pathology: in the future morphological pathology alone is
still essential but is certainly not sufficient. This established discipline
can be only enhanced by the new parallel, morphomolecular
pathology.
Avoiding training (r)evolution will hinder and fragment the
progress of molecular diagnostics, providing a less integrated
approach to molecular tissue pathology, which may not deliver the
full promise of molecular medicine to our patients.
Hereby, we strongly encourage national training bodies to rise to
the challenge that the 100 000 Genomes Project, and many other
initiatives, are now posing: the systematic and profound review of the
Pathology training curriculum to adapt the new generation of
pathologists to a new era. The challenge is not small. Training
programmes would need to maintain their current training for
primary morphologists, as this is a demand that will never end,
and, in parallel, begin to deliver training programmes that will allow
a cadre of trainees to pursue a true morphomolecular career.
This may require a commitment to subspecialisation earlier on in
training and may take the form of parallel, modular training
programmes delivered by a group of specialist centres, which
would provide exposure to a diversity of training. It may also require
an almost one-to-one training plan and evaluation scheme.
This complexity in training will be necessary to prepare our
pathologists for the increased diagnostic complexity of modern
medicine.
It is our view that maintaining the status quo will be detrimental
for both the next generation of pathologists, for the specialty as a
whole, and for the future of molecular diagnostics and precision
medicine. Whether or not we embrace this radical change, the
future of pathology is our responsibility. Our generation needs to
carefully consider the challenge of adapting to this genomic era,
and, if we do not act soon, we may be the last generation of
pathologists able to do so. Embracing this challenge will prove that,
once again, pathology has managed to adapt successfully to yet
another transformative challenge.
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